GlaxoSmithKline plc (LON:GSK)‘s stock had its “neutral” rating reaffirmed by research analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday. They currently have a GBX 1,670 ($20.62) target price on the stock. JPMorgan Chase & Co.’s price objective points to a potential downside of 1.10% from the company’s previous close.
Several other analysts have also recently commented on GSK. Deutsche Bank AG set a GBX 1,760 ($21.74) price objective on shares of GlaxoSmithKline plc and gave the company a “neutral” rating in a research note on Wednesday, November 30th. Goldman Sachs Group Inc restated a “buy” rating on shares of GlaxoSmithKline plc in a research report on Thursday, December 1st. Beaufort Securities restated a “buy” rating on shares of GlaxoSmithKline plc in a research report on Monday, December 5th. HSBC Holdings plc restated a “buy” rating and set a GBX 1,970 ($24.33) target price on shares of GlaxoSmithKline plc in a research report on Tuesday, December 13th. Finally, Shore Capital restated a “hold” rating on shares of GlaxoSmithKline plc in a research report on Thursday, December 15th. Three investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have assigned a buy rating to the company. GlaxoSmithKline plc presently has an average rating of “Hold” and an average target price of GBX 1,744.73 ($21.55).
GlaxoSmithKline plc (LON:GSK) opened at 1688.50 on Tuesday. GlaxoSmithKline plc has a 52-week low of GBX 1,363.00 and a 52-week high of GBX 1,745.56. The company’s 50 day moving average is GBX 1,626.62 and its 200-day moving average is GBX 1,592.90. The stock’s market cap is GBX 82.20 billion.
The business also recently announced a dividend, which will be paid on Thursday, April 13th. Investors of record on Thursday, February 23rd will be issued a GBX 23 ($0.28) dividend. This represents a yield of 1.47%. This is an increase from GlaxoSmithKline plc’s previous dividend of $19.00. The ex-dividend date is Thursday, February 23rd.
var userip;Your IP Address: document.write(userip);
In related news, insider Moncef Slaoui bought 56 shares of the stock in a transaction that occurred on Tuesday, March 7th. The stock was purchased at an average cost of GBX 2,072 ($25.59) per share, for a total transaction of £1,160.32 ($1,433.02). Also, insider Simon Dingemans sold 3,589 shares of the business’s stock in a transaction that occurred on Wednesday, February 22nd. The shares were sold at an average price of GBX 1,640 ($20.25), for a total transaction of £58,859.60 ($72,693.10). Over the last 90 days, insiders purchased 471 shares of company stock valued at $786,697 and sold 52,038 shares valued at $84,442,106.
About GlaxoSmithKline plc
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.